Omalizumab (Xolair) treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria

The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2015, 2015
Series:Common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment
Physical Description:1 PDF file illustrations